Literature DB >> 8148220

Oxidative activation of proguanil and dapsone acetylation in Thai soldiers.

M D Edstein1, G D Shanks, P Teja-Isavadharm, K H Rieckmann, H K Webster.   

Abstract

The prevalence of putative poor metaboliser (PM) phenotypes of proguanil oxidation in Caucasian populations is 3-10%. The PM frequency in Oriental populations is unknown. In this study the plasma metabolic ratios of proguanil and dapsone to their principal metabolites cycloguanil and monoacetyldapsone were determined in Thai soldiers receiving antifolate drug combinations for malaria prophylaxis. The distribution ratio of proguanil to cycloguanil (PROG/CYC) was highly skewed with no evidence of bimodality. Assuming subjects with a PROG/CYC ratio greater than 10 are PMs from studies in Caucasians, the incidence of PMs in the soldiers would be 18% (30 of 170). The mean PROG/CYC ratio for PMs in the Thai soldiers was 31.2 +/- 28.9 (n = 30) compared with 25.5 +/- 2.5 (n = 3) in a study of Caucasians. The corresponding values for putative EMs were 5.4 +/- 2.1 (n = 140) and 2.4 +/- 0.2 (n = 134). Similar to other Oriental populations, Thais were found to be predominantly (76%, 173 of 228) rapid acetylators of dapsone.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8148220      PMCID: PMC1364712          DOI: 10.1111/j.1365-2125.1994.tb04241.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.

Authors:  S A Ward; W M Watkins; E Mberu; J E Saunders; D K Koech; H M Gilles; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

Review 2.  Disease and acetylation polymorphism.

Authors:  P K Lunde; K Frislid; V Hansteen
Journal:  Clin Pharmacokinet       Date:  1977 May-Jun       Impact factor: 6.447

3.  Hydralazine elimination in man.

Authors:  M M Reidenberg; D Drayer; A L DeMarco; C T Bello
Journal:  Clin Pharmacol Ther       Date:  1973 Nov-Dec       Impact factor: 6.875

4.  N-acetyltransferase polymorphism in Thailand.

Authors:  V Kukongviriyapan; V Lulitanond; C Areejitranusorn; B Kongyingyose; P Laupattarakasem
Journal:  Hum Hered       Date:  1984       Impact factor: 0.444

5.  Proguanil-sulphonamide for malaria prophylaxis.

Authors:  J J Karwacki; G D Shanks; N Limsomwong; P Singharaj
Journal:  Trans R Soc Trop Med Hyg       Date:  1990 Jan-Feb       Impact factor: 2.184

6.  Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone.

Authors:  M D Edstein; J R Veenendaal; K H Rieckmann
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

7.  Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine.

Authors:  R A Ahmad; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

8.  Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects.

Authors:  Y Wattanagoon; R B Taylor; R R Moody; N A Ochekpe; S Looareesuwan; N J White
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

9.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.

Authors:  Y Horai; M Nakano; T Ishizaki; K Ishikawa; H H Zhou; B I Zhou; C L Liao; L M Zhang
Journal:  Clin Pharmacol Ther       Date:  1989-08       Impact factor: 6.875

10.  Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.

Authors:  P J Wedlund; W S Aslanian; C B McAllister; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

View more
  5 in total

1.  Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population.

Authors:  S Wanwimolruk; M R Thou; D J Woods
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

2.  Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.

Authors:  J K Coller; A A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

3.  Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil.

Authors:  R McGready; K Stepniewska; E Seaton; T Cho; D Cho; A Ginsberg; M D Edstein; E Ashley; S Looareesuwan; N J White; F Nosten
Journal:  Eur J Clin Pharmacol       Date:  2003-08-30       Impact factor: 2.953

4.  The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria.

Authors:  R McGready; K Stepniewska; M D Edstein; T Cho; G Gilveray; S Looareesuwan; N J White; F Nosten
Journal:  Eur J Clin Pharmacol       Date:  2003-08-30       Impact factor: 2.953

5.  Phenotyping and genotyping of CYP2C19 using comparative metabolism of proguanil in sickle-cell disease patients and healthy controls in Nigeria.

Authors:  Olufunmilayo E Adejumo; Taiwo R Kotila; Adeyinka G Falusi; Boladale O Silva; Jacinta N Nwogu; Pius S Fasinu; Chinedum P Babalola
Journal:  Pharmacol Res Perspect       Date:  2016-08-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.